SONN News - Candlesense

Sonnet Releases Virtual Investor "What This Means" Segment

- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)

How does the expansion align with Sonnet's overall pipeline and strategic priorities? What is the anticipated impact on Sonnet's stock price in the short term? How might the trial expansion impact Sonnet's share dilution or financing needs?

Clinical trials

13 days ago